Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
about
Adjuvant radiotherapy following radical prostatectomy for prostate cancerNeo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancerSafety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvantA patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trialsIntensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerContemporary Management of Prostate CancerPrevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelConcurrent chemoradiation for high-risk prostate cancerOptimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysisTreatment options for localized prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapyCombination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I studyEnhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumorsDiscerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancerProspective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancerHigh-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-upThe long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology.Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysisAdjuvant medical therapy for prostate cancer.Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparisonThe relevance of the procedures related to the physiotherapy in the interventions in patients with prostate cancer: short review with practice approach.Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updateSunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Bone health and prostate cancer.Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerRTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancerAdjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsAn update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsAndrogen deprivation therapy for prostate cancer: indications, contraindications and possible consequences.Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy.Radiation therapy in prostate cancer: a risk-adapted strategy.Multimodal approaches to high-risk prostate cancer.Androgen deprivation therapy for prostate cancer-review of indications in 2010
P2860
Q24234347-ED8ADBE8-E4A4-4D16-B5F9-C3C01ACF3194Q24244156-38296527-B586-4A12-A6A7-2CABFD4518C1Q24655036-EAD1EC00-1C90-45E6-BCEA-61C342D2E8A3Q24658584-9C121E63-CA70-40AF-AC7E-EA7941A8DF22Q24815261-132B066A-7392-40F5-AE7A-331DD09BD670Q26747782-133B9F22-240C-46FA-AB52-20BFF42F5F00Q26767456-3E6D8E6B-8EFB-496E-B14F-F47FC2F5F847Q26783861-29585B8F-9F07-4062-B2FD-5006A9A6A80DQ26798912-4CF8B872-52B5-4FFE-ACCC-8E5967BC532BQ26801000-21A9917D-1FEA-47AC-BD35-EC4DB5E40C51Q26825653-E40A23B8-D38B-43DD-AD80-2929EC83E3BAQ27022847-690489D4-8A83-4195-A3A3-3A0476B51B1CQ27308917-D7CBE253-2E7B-4B17-AC99-CE0D7BAA1621Q28218423-7FBFF8F7-4A82-4B61-8853-3F8AA178F470Q30408302-6404E96B-0AF9-4A40-AF1E-C95FF89ABA95Q31155248-BB5E70CC-A338-4473-AD2E-D13D053BA237Q33304413-BFA4EECE-B3D2-454F-83EA-3548AD7333D7Q33351115-2AC149E6-E1F0-43C1-AD03-EEAA5ADAA9E6Q33415382-6C002418-235B-4A40-AED8-1E3557A329C8Q33582598-4EAAC562-8758-4798-95CD-4F21146D992AQ33609747-587F7B3F-339E-4D16-A4C9-0B86496B98D6Q33613683-FE4828EE-11EC-4AB4-B56A-B15B13D2549DQ33758771-CBDA967F-262C-4AF1-896B-BD6AA1A39189Q33766974-218B1717-36D8-4C4F-BF5D-DB9607853500Q33878106-61F65245-5299-420C-A012-7F4FD1D31411Q33882588-9E5D3320-ED6A-4EA5-A869-23217116E645Q33893647-583A2E09-BCB5-4790-8BEE-7856317611B6Q33900049-AC84D018-732C-490E-B57A-BE1FFBDF76E2Q33918464-90962425-38DC-4FAF-A007-4C54009F60D7Q33977523-4AE5793D-4D50-4B9F-B7AB-CB3E13B8F1F3Q33977536-43ACDF71-8221-42A8-9C94-7496DFB30FACQ33978286-78C5E023-5E33-4D20-9950-03C911652607Q33999745-B9D53B10-1FCE-4957-B5D2-FC1FF08E13C7Q34013808-4CB3D122-B203-4F2A-B0D5-7E98FE9852EBQ34048630-7D7731AF-3F33-4C7D-9632-B74DA9DCFC00Q34062385-7A57CB4A-295B-4979-A673-2D711F36358AQ34106261-DAE1E7F7-A617-4328-AEAF-31CF40873B43Q34111590-0CCE446D-34BC-4D73-9ED9-663027068AE4Q34111597-7B448EB6-5EB9-4BC4-AFC6-31CC44BDEB5FQ34111603-23B36252-7D1F-415E-8ED8-7581175BEFA3
P2860
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Long-term results with immedia ...... a phase III randomised trial.
@en
Long-term results with immedia ...... cally advanced prostate cancer
@nl
type
label
Long-term results with immedia ...... a phase III randomised trial.
@en
Long-term results with immedia ...... cally advanced prostate cancer
@nl
prefLabel
Long-term results with immedia ...... a phase III randomised trial.
@en
Long-term results with immedia ...... cally advanced prostate cancer
@nl
P2093
P1433
P1476
Long-term results with immedia ...... a phase III randomised trial.
@en
P2093
Abraham Kuten
Alfredo Zurlo
Carmel Lino Cutajar
Cora Sternberg
Guy Storme
J Rafael Pfeffer
Jacques Bernier
Jean Bernard Dubois
Johan Mattelaer
José Lopez Torecilla
P304
P356
10.1016/S0140-6736(02)09408-4
P407
P577
2002-07-01T00:00:00Z